Geron Co. (NASDAQ:GERN)’s share price traded up 8.8% during trading on Monday . The stock traded as high as $2.20 and last traded at $2.10, 5,960,509 shares traded hands during trading. An increase of 138% from the average session volume of 2,501,570 shares. The stock had previously closed at $1.93.
Several equities analysts have recently commented on the stock. BidaskClub upgraded shares of Geron from a “sell” rating to a “hold” rating in a research report on Tuesday. Needham & Company LLC restated a “buy” rating and set a $3.00 price target on shares of Geron in a research report on Wednesday, June 17th. B. Riley upped their price target on shares of Geron from $3.50 to $4.00 and gave the stock a “buy” rating in a research report on Friday, May 29th. ValuEngine lowered shares of Geron from a “buy” rating to a “hold” rating in a research report on Monday, March 16th. Finally, Cantor Fitzgerald increased their target price on shares of Geron from $3.00 to $4.00 and gave the company an “overweight” rating in a research report on Monday, June 1st. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $3.29.
The stock’s 50-day moving average is $1.74 and its 200-day moving average is $1.37. The stock has a market cap of $426.97 million, a P/E ratio of -5.59 and a beta of 1.76. The company has a current ratio of 7.93, a quick ratio of 7.93 and a debt-to-equity ratio of 0.04.
Several large investors have recently bought and sold shares of GERN. Bank of Montreal Can boosted its position in shares of Geron by 47.4% during the 4th quarter. Bank of Montreal Can now owns 24,073 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 7,742 shares in the last quarter. Prudential Financial Inc. boosted its position in shares of Geron by 67.7% during the 4th quarter. Prudential Financial Inc. now owns 23,618 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 9,531 shares in the last quarter. Arizona State Retirement System bought a new position in shares of Geron during the 1st quarter valued at about $56,000. BNP Paribas Arbitrage SA boosted its position in shares of Geron by 101.7% during the 1st quarter. BNP Paribas Arbitrage SA now owns 57,639 shares of the biopharmaceutical company’s stock valued at $69,000 after purchasing an additional 29,069 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Geron during the 4th quarter valued at about $78,000. Institutional investors own 30.64% of the company’s stock.
About Geron (NASDAQ:GERN)
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production.
Featured Story: Insider Trading
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.